Literature DB >> 31818816

Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model.

Tomefa E Asempa1, Kamilia Abdelraouf1, Teresa Carabeo2, Raymond Schuch2, David P Nicolau3,4.   

Abstract

We evaluated the efficacy of escalating doses of exebacase administered with subtherapeutic daptomycin exposures against 8 Staphylococcus aureus isolates in a neutropenic murine thigh infection model. Daptomycin alone resulted in mean growth of 0.39 ± 1.19 log10 CFU/thigh. When administered with daptomycin, exebacase resulted in a mean log10 CFU/thigh reduction of -1.03 ± 0.72 (range, -0.77 ± 0.98 to -1.20 ± 0.59) across evaluated doses (15 to 90 mg/kg), indicative of potential in vivo synergy.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus; combination therapy; lysin; methicillin-resistant S. aureus (MRSA); methicillin-susceptible S. aureus (MSSA)

Mesh：

Substances：

Year:  2020        PMID： 31818816      PMCID： PMC7038299          DOI： 10.1128/AAC.02176-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.

Authors:  Jun Taek Oh; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Recombinant bacteriophage lysins as antibacterials.

Authors:  Mark Fenton; Paul Ross; Olivia McAuliffe; Jim O'Mahony; Aidan Coffey
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

3.  The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis.

Authors:  Chiara Indiani; Karen Sauve; Assaf Raz; Wessam Abdelhady; Yan Q Xiong; Cara Cassino; Arnold S Bayer; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database.

Authors:  Gary A Noskin; Robert J Rubin; Jerome J Schentag; Jan Kluytmans; Edwin C Hedblom; Maartje Smulders; Elizabeth Lapetina; Eric Gemmen
Journal:  Arch Intern Med       Date:  2005 Aug 8-22

5.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

Review 6.  Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments.

Authors:  Michael Wittekind; Raymond Schuch
Journal:  Curr Opin Microbiol       Date:  2016-05-31       Impact factor: 7.934

7.  Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus.

Authors:  Aubrey Watson; Karen Sauve; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 8.  Bacteriophage lysins as effective antibacterials.

Authors:  Vincent A Fischetti
Journal:  Curr Opin Microbiol       Date:  2008-10-14       Impact factor: 7.934

9.  Determining bacteriophage endopeptidase activity using either fluorophore-quencher labeled peptides combined with liquid chromatography-mass spectrometry (LC-MS) or Förster resonance energy transfer (FRET) assays.

Authors:  Rolf Lood; Henrik Molina; Vincent A Fischetti
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

10.  Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.

Authors:  Raymond Schuch; Han M Lee; Brent C Schneider; Karen L Sauve; Christina Law; Babar K Khan; Jimmy A Rotolo; Yuki Horiuchi; Daniel E Couto; Assaf Raz; Vincent A Fischetti; David B Huang; Robert C Nowinski; Michael Wittekind
Journal:  J Infect Dis       Date:  2013-11-28       Impact factor: 5.226
View more
  6 in total

1.  The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models.

Authors:  Tomefa E Asempa; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Exebacase in Addition to Daptomycin against MRSA.

Authors:  Razieh Kebriaei; Kyle C Stamper; Katherine L Lev; Taylor Morrisette; Jacinda C Abdul-Mutakabbir; Raymond Schuch; Dario Lehoux; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

Review 3.  Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance.

Authors:  Raymond Schuch; Cara Cassino; Xavier Vila-Farres
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

4.  Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis.

Authors:  Melissa Karau; Suzannah Schmidt-Malan; Jay Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel
Journal:  J Bone Jt Infect       Date:  2022-07-27

5.  Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections.

Authors:  Aubin Souche; Camille Kolenda; Jordan Teoli; Raymond Schuch; Tristan Ferry; Frédéric Laurent; Jérôme Josse
Journal:  Antimicrob Agents Chemother       Date:  2022-07-11       Impact factor: 5.938

Review 6.  Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.

Authors:  Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Stephen T Abedon
Journal:  Antibiotics (Basel)       Date:  2021-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.